MedTrace Logo

Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography

NCT03779815 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-04-18

No results posted yet for this study

Summary

\[18F\]Florbetaben PET/CT imaging will noninvasively assess amyloid deposition in systemic amyloidosis.

Conditions

Interventions

DRUG

[18F]Florbetaben

* Drug: \[18F\]Florbetaben * \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma * Other name: Neuraceq * Amount: 300 MBq ± 20% bolus, 10mL intravenously

Sponsors & Collaborators

  • Ulsan University Hospital

    lead OTHER

Principal Investigators

  • Jae-Cheol Jo, PhD · Ulsan University Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03779815 on ClinicalTrials.gov